Drug-resistant tuberculosis is a substantial health-care concern worldwide. Despite culture-
based methods being considered the gold standard for drug susceptibility testing, molecular …

This article provides an encompassing review of the current pipeline of putative and
developed treatments for tuberculosis, including multidrug-resistant strains. The review has …

In the past few decades, drug-resistant (DR) strains of Mycobacterium tuberculosis (M. tb),
the causative agent of tuberculosis (TB), have become increasingly prevalent and pose a …

The mortality incidence from nontuberculous mycobacteria (NTM) infections has been
steadily developing globally. These bacterial agents were once thought to be innocent …

Delamanid, bedaquiline, and pretomanid have been recently added in the anti-tuberculosis
(anti-TB) treatment regimens and have emerged as potential solutions for combating drug …

Tuberculosis (TB) is currently the second deadliest infectious disease. Existing
antitubercular therapies are long, complex, and have severe side effects that result in low …

Tuberculosis (TB) is a major global health problem and the second most prevalent infectious
killer after COVID-19. It is caused by Mycobacterium tuberculosis (Mtb) and has become …

The prevalence of tuberculosis (TB) remains the leading cause of death from a single
infectious agent, ranking it above all other contagious diseases. The problem to tackle this …

Tuberculosis remains the leading cause of death from a single pathogen. On the other hand,
antimicrobial resistance (AMR) makes it increasingly difficult to deal with this disease. We …

Pyrazinamide (PZA) is an essential first-line tuberculosis drug for its unique mechanism of
action active against multidrug-resistant-TB (MDR-TB). Thus, the aim of updated meta …